EODData

MEMBERSHIP REGISTER LOG IN

FRA, PMRA: Pharma Mar SAU

13 Feb 2026
LAST:

75.70

CHANGE:
 0.25		OPEN:
75.70		HIGH:
75.70		ASK:
0.00		VOLUME:
300
CHG(%):
0.33		PREV:
75.95		LOW:
75.70		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Feb 2675.7075.7075.7075.70300
12 Feb 2675.9575.9575.9575.95300
11 Feb 2677.8077.8077.8077.80300
10 Feb 2676.3076.3076.3076.30300
09 Feb 2676.3076.3076.3076.30300
06 Feb 2675.6575.6575.6575.65300
05 Feb 2676.8076.8076.8076.80300
04 Feb 2677.4077.4076.7576.75300
03 Feb 2676.8076.8076.8076.808
02 Feb 2677.6577.6577.6577.658

PROFILE

Name:Pharma Mar SAU
About:Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Sector:Healthcare
Industry:Biotechnology
Address:Avenida de los Reyes, 1, Madrid, Spain, 28770
Website:https://www.pharmamar.com
ISIN:ES0169501022
LEI:959800QWKZ45ZQC2AV58

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:38.85 
Price to Sales:7.25 
Price to Book:6.69 
Profit Margin:0.19 
Operating Margin:-0.11 
Return on Assets:0.04 
Return on Equity:0.18 
DivYield:0.01 
Div/Share:0.80 
Revenue:179.28M 
EBITDA:21.05M 
Shares:17.43M 
Market Cap:1.32B 

TECHNICAL INDICATORS

MA5:76.410.9%
MA10:76.571.1%
MA20:78.313.4%
MA50:77.061.8%
MA100:78.653.9%
MA200:80.226.0%
STO9:2.33 
STO14:0.98 
RSI14:20.47 
WPR14:-99.02 
MTM14:-5.05
ROC14:-0.06 
ATR:0.81 
Week High:77.802.8%
Week Low:75.650.1%
Month High:82.909.5%
Month Low:75.656.0%
Year High:101.1833.7%
Year Low:70.607.2%
Volatility:17.71 

RECENT SPLITS

Date Ratio
22 Jul 20201-12

RECENT DIVIDENDS

Date Amount
25 Jun 2025$0.80
12 Jun 2024$0.65
07 Jun 2023$0.65
13 Jul 2022$0.65
28 Apr 2021$0.60
26 Jun 2020$0.48